Abstract Number: 1841 • ACR Convergence 2024
Preclinical Evaluation of ALLO-329: Allogeneic CD19 CAR T Cells Expressing an Anti-Rejection CD70 CAR for the Treatment of Autoimmune Diseases
Background/Purpose: Autologous CD19 chimeric antigen receptor (CAR) T cell therapies have recently shown to be well tolerated and highly effective in patients with autoimmune diseases…Abstract Number: 2550 • ACR Convergence 2024
Infiltrating and Resident Macrophages in Lupus Nephritis: Scar Associated Macrophage Phagocytic Dysfunction and Fibroblast Activation
Background/Purpose: Lupus nephritis (LN) is driven by a heterogeneous population of renal macrophages. We have previously reported that the renal macrophage subpopulations are similar in…Abstract Number: 0008 • ACR Convergence 2024
Preclinical Development and Manufacturability of KYV-201, an Investigational Allogeneic Anti-CD19 Chimeric Antigen Receptor T Cell for the Treatment of Autoimmune Disease
Background/Purpose: Autologous anti-CD19 chimeric antigen receptor (CAR) T cells show early clinical evidence of safety and efficacy for treating several autoimmune diseases (Müller F. N Engl…Abstract Number: 0640 • ACR Convergence 2024
7000-Plex Proteomic Screen of Urine for Flare Monitoring and Treatment Response Biomarkers in Active Lupus Nephritis
Background/Purpose: Lupus nephritis (LN) is a major cause of morbidity and mortality in patients with lupus. Since the kidney biopsy is invasive, better, more predictive…Abstract Number: 0811 • ACR Convergence 2024
High-Throughput Proteomic Profiling of Longitudinal Serum Samples to Predict Treatment Response in Lupus Nephritis
Background/Purpose: Lupus nephritis (LN) can lead to severe morbidity and early mortality in SLE patients. While therapeutic options for LN have improved, they are not…Abstract Number: 1536 • ACR Convergence 2024
Prescription Rates of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Lupus Nephritis: A Comparative Study Across Specialties
Background/Purpose: Lupus nephritis is a well-known and severe complication in patients with systemic lupus erythematosus (SLE) that can lead to significant morbidity and mortality. Angiotensin-converting…Abstract Number: 1870 • ACR Convergence 2024
Costs and Healthcare Resource Utilization Associated with Inpatient and Day Hospitalizations of Patients with Lupus and Psychiatric Manifestations in France
Background/Purpose: Lupus, a rare chronic autoimmune disorder, severely impacts patients' quality of life, productivity, and survival, placing a heavy burden on the healthcare system. Up…Abstract Number: 2575 • ACR Convergence 2024
Can Immunosuppressive Therapy Be Safely Discontinued in Patients with Lupus Nephritis?
Background/Purpose: The latest guidelines for managing lupus nephritis (LN), including the 2024 KDIGO guidelines and the 2019 EULAR/ERA-EDTA update, recommend a minimum immunosuppression (IS) duration…Abstract Number: 0018 • ACR Convergence 2024
Preclinical Analysisof CB-010, an Allogeneic anti-CD19CAR-T Cell Therapywith a PD-1 Knockout, for the Treatment of Patients with Refractory Systemic Lupus Erythematosus (SLE)
Background/Purpose: Autologous CD19-directed CAR-T cell therapy has been shown to eradicate aberrant B cells leading to durable clinical responses in SLE patients (Müller 2024; Wang 2024). However, autologous CAR-T cell…Abstract Number: 0646 • ACR Convergence 2024
Chart Audit of over 1,000 SLE Patients Reveals Biologic Treatment Choice Driven by Disease Manifestations
Background/Purpose: To better understand how US rheumatologists utilize biologics in the management of SLE, especially among those with cutaneous manifestations. No medication is currently FDA-approved…Abstract Number: 0812 • ACR Convergence 2024
A Human Gut Pathobiont Drives Platelet Activation with Microparticle Release and NETosis During Lupus Nephritis Flares
Background/Purpose: SLE is a leading cause of premature death, often from severe complications including lupus nephritis (LN), especially in disadvantaged groups. Despite advances in treatment,…Abstract Number: 1538 • ACR Convergence 2024
Patient Reported Outcomes Analyses from AURORA 1 Clinical Trial: Lupus Impact Tracker and LupusPRO
Background/Purpose: Voclosporin used in addition to Mycophenolate Mofetil and low dose oral steroids in patients with active Lupus Nephritis (LN) was found to be superior…Abstract Number: 1873 • ACR Convergence 2024
Race/Ethnicity and Household Income at the County Level Interacts with the Association of Urbanicity and Lupus Nephritis Mortality
Background/Purpose: The reasons underlying substantial variation in lupus nephritis (LN) deaths by race/ethnicity remain largely unknown. There are no large population-based studies focused on the…Abstract Number: 2576 • ACR Convergence 2024
Glucagon-Like Peptide-1 Receptor Agonist Use and the Risk of Adverse Cardiac and Kidney Outcomes Among Patients with Systemic Lupus Erythematosus and Lupus Nephritis
Background/Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1RA) are hypoglycemic agents with well-established cardioprotective properties and emerging data for kidney-protective benefits in patients with type 2 diabetes…Abstract Number: 0085 • ACR Convergence 2024
A Novel, Potent and Selective TLR7/8 Small Molecule Inhibitor Blocks TLR7/8 Pathway in the Presence of HCQ and Demonstrates Robust Preclinical Efficacy in Lupus Models
Background/Purpose: Toll-like receptor 7, 8 and 9 (TLR7/8/9) are endosomal nucleic acid sensors that when aberrantly activated, induce Type I interferon (IFNα), proinflammatory cytokines, immune…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 37
- Next Page »